AstraZeneca at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
AstraZeneca takes part in 3 sessions at BIO-Europe 2026 in Cologne. Its sessions cover AI in the lab, clinical trial systems and greener biopharma partnerships. One asks why the efficiency AI brings could mean more drugs rather than fewer research jobs.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. Ecosystem InnovationBusiness of Biotech Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. Panel Wed Nov 11 11:00–11:30 Sustainability & Innovation: Transforming Biopharma Partnerships for a Greener Future How drug companies, smaller firms and suppliers can team up to cut supply chain carbon emissions and bring greener technologies to industrial scale. |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction